(Q33940347)

30 July 2017

1 reference

title

Sporadic endocrine tumours and their relationship to the hereditary endocrine neoplasia syndromes (English)

1 reference

30 July 2017

Koper JW

1

1 reference

PubMed ID

10849017

30 July 2017

Lamberts SW

series ordinal

2

1 reference

30 July 2017

1 June 2000

1 reference

European Journal of Clinical Investigation

30 July 2017

1 reference

30 July 2017

30

1 reference

30 July 2017

493-500

1 reference

30 July 2017

6

1 reference

Identification of the von Hippel-Lindau disease tumor suppressor gene

30 July 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Positional cloning of the gene for multiple endocrine neoplasia-type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Genetic testing for cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Germline mutations in the vhl gene in patients presenting with phaeochromocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Mutations of the VHL tumour suppressor gene in renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Novel somatic mutations in the VHL gene in Swedish archived sporadic renal cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Inhibition of transcription elongation by the VHL tumor suppressor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Molecular cloning of an essential subunit of RNA polymerase II elongation factor SIII

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Elongin (SIII): a multisubunit regulator of elongation by RNA polymerase II

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Menin, the product of the MEN1 gene, is a nuclear protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Characterization of mutations in patients with multiple endocrine neoplasia type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Germ-line mutation analysis in patients with multiple endocrine neoplasia type 1 and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

DNA secondary structures and the evolution of hypervariable tandem arrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Somatic mutation of the MEN1 gene in parathyroid tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Activation of a novel human transforming gene, ret, by DNA rearrangement

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and hirschsprung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Mutational analysis of the RET proto-oncogene in 71 Japanese patients with medullary thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

GDNF signalling through the Ret receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Functional receptor for GDNF encoded by the c-ret proto-oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Catalytic specificity of protein-tyrosine kinases is critical for selective signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Human Cancer Syndromes: Clues to the Origin and Nature of Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Clinical management of the multiple endocrine neoplasia syndromes: results of a computerized opinion poll at the Sixth International Workshop on Multiple Endocrine Neoplasia and von Hippel-Lindau disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Genetic testing and early thyroidectomy for inherited medullary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Structure and distribution of rat menin mRNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Characterization of the MEN1 gene product, menin, by site-specific polyclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Stable overexpression of MEN1 suppresses tumorigenicity of RAS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Isolation, genomic organization, and expression analysis of Men1, the murine homolog of the MEN1 gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

The human gene mutation database

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

Mutation of theRET protooncogene in sporadic medullary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2000.00666.X

10.1046/J.1365-2362.2000.00666.X

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

10849017